Circular RNA EIF4G3 suppresses gastric cancer progression through inhibition of β-catenin by promoting δ-catenin ubiquitin degradation and upregulating SIK1

• Main Authors: Cai, H. (Author), Chen, Y. (Author), Fu, M. (Author), Gu, J. (Author), Jiang, J. (Author), Qian, H. (Author), Shi, H. (Author), Wang, M. (Author), Xu, W. (Author), Zang, X. (Author), Zhang, X. (Author), Zhang, Y. (Author)
• Format: Article
• Language: English
• Published: BioMed Central Ltd 2022
• Subjects: Circular RNA; Gastric cancer; SIK1; TRIM25; δ-catenin
• Online Access: View Fulltext in Publisher
• ISBN: 14764598 (ISSN)
• DOI: 10.1186/s12943-022-01606-9

Background: Increasing studies suggest that circular RNAs (circRNAs) are critical regulators of cancer development and progression. However, the biological roles and mechanisms of circRNAs in gastric cancer (GC) remain largely unknown. Methods: We identified the differentially expressed circRNAs in GC by analyzing Gene Expression Omnibus (GEO) datasets. We explored the biological roles of circRNAs in GC by in vitro functional assays and in vivo animal studies. We performed tagged RNA affinity purification (TRAP), RNA immunoprecipitation (RIP), mass spectrometry (MS), RNA sequencing, luciferase reporter assays, and rescue experiments to investigate the mechanism of circRNAs in GC. Results: Downregulated expression of circular RNA EIF4G3 (circEIF4G3; hsa_circ_0007991) was found in GC and was associated with poor clinical outcomes. Overexpression of circEIF4G3 suppressed GC growth and metastasis through the inhibition of β-catenin signaling, whereas knockdown of circEIF4G3 showed the opposite effects. Mechanistic studies revealed that circEIF4G3 bound to δ-catenin protein to promote its TRIM25-mediated ubiquitin degradation and interacted with miR-4449 to upregulate SIK1 expression. Conclusion: Our findings uncovered a tumor suppressor function of circEIF4G3 in GC through the regulation of δ-catenin protein stability and miR-4449/SIK1 axis. CircEIF4G3 may act as a promising prognostic biomarker and therapeutic target for GC. © 2022, The Author(s).